Lund F, Ekeström S, Frisch E P, Magaard F
Angiology. 1975 Jul-Aug;26(7):534-56. doi: 10.1177/000331977502600707.
The material includes 17 patients suffering from different degrees of chronic peripheral arterial disease (11 chronic patients stage III and IV, two patients with acute arterial occlusion, and four patients stage II). Presence and extent of arterial occlusion was ascertained by initial arteriography. In twelve of the patients amputation had been considered. The patients were treated by a series of i.v. infusions of brinase, a proteolytic enzyme from Aspergillus oryzae. The brinase inhibitor capacity in plasma was determined by the azocollagen technique. Dosage of brinase was calculated to retain a rest-inhibitor capacity in order to avoid free proteolytic activity. In five patients the enzyme was also given preoperatively by intra-arterial instillation prior to a series of i.v. brinase infusions. Thirteen patients showed clinical improvement after brinase treatment. The condition of two patients remained unchanged, and in two patients amputation could not be avoided. In fourteen patients the treatment results were followed by measurement of peripheral systolic blood pressure. In ten patients obvious increase of the peripheral systolic blood pressure was observed. Cutaneous microcirculation was studied in seven patients by i.v. sequential fluorescein angiography and signs of improved microcirculation (appearance time, intensity and/or extent of fluorescence) were found in all examined patients. One patient with acute arterial occlusion of the right leg with obstruction of blood flow from the external iliac artery showed complete disobliteration after a series of i.v. brinase infusions. Bleeding complications associated with brinase treatment were not observed in the material. In three patients brinase treatment was discontinued because of complications (2 brinase, 1 heparin).
该材料包括17例患有不同程度慢性外周动脉疾病的患者(11例慢性III期和IV期患者、2例急性动脉闭塞患者以及4例II期患者)。通过初始血管造影确定动脉闭塞的存在和程度。12例患者曾考虑过截肢。患者接受了一系列静脉输注米曲霉蛋白水解酶brinase的治疗。采用偶氮胶原技术测定血浆中brinase抑制剂的能力。计算brinase的剂量以保持残余抑制剂能力,以避免游离蛋白水解活性。5例患者在进行一系列静脉brinase输注之前,还在术前通过动脉内滴注给予该酶。13例患者在brinase治疗后临床症状改善。2例患者病情未变,2例患者无法避免截肢。14例患者在治疗后测量了外周收缩压。10例患者观察到外周收缩压明显升高。7例患者通过静脉序贯荧光血管造影术研究了皮肤微循环,所有接受检查的患者均发现微循环改善的迹象(荧光出现时间、强度和/或范围)。1例右下肢急性动脉闭塞、血流从髂外动脉受阻的患者在进行一系列静脉brinase输注后显示完全再通。该材料中未观察到与brinase治疗相关的出血并发症。3例患者因并发症(2例与brinase有关,1例与肝素有关)而停止brinase治疗。